Click to view your profile
Click to search for condition or expert
Click to open main menu
Waldenstrom Macroglobulinemia Latest Advances
Find the Latest Research About Waldenstrom Macroglobulinemia
Save
Bookmark
Share
Share
Overview
Find a Doctor
Latest Advances
Clinical Trials
Treatments
Customize your search results with filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 01/20/2023
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 47 publications
See more filters
Successful and safe response to ibrutinib alone in treating relapsed Waldenström macrogobulinemia and related acquired von Willebrand syndrome: an option to consider.
Condition:
Relapsed Waldenström Macrogobulinemia (WM) and Related Acquired von Willebrand Syndrome (AVWS)
Journal:
Leukemia & lymphoma
Treatment Used:
Ibrutinib
Number of Patients:
2
Published:
December 17, 2022
VIEW PUBLICATION
A Canadian Perspective on the Treatment of Waldenström Macroglobulinemia.
Condition:
Waldenström Macroglobulinemia (WM)
Journal:
Current oncology (Toronto, Ont.)
Treatment Used:
Bendamustine-Rituximab, Bruton's TKIs, Proteasome Inhibitor, Purine Analogue, Chemoimmunotherapy, and Autologous Stem Cell Transplantation
Number of Patients:
0
Published:
October 27, 2022
VIEW PUBLICATION
Coming of Age for BTK Inhibitor Therapy: A Review of Zanubrutinib in Waldenström Macroglobulinemia.
Condition:
Waldenström Macroglobulinemia (WM)
Journal:
Cells
Treatment Used:
Zanubrutinib
Number of Patients:
0
Published:
October 27, 2022
VIEW PUBLICATION
IBCL-376 Early Therapy Intensification for High-Risk Waldenström Macroglobulinemia.
Condition:
High-Risk Waldenström Macroglobulinemia
Journal:
Clinical lymphoma, myeloma & leukemia
Treatment Used:
Intensive Induction Immunochemotherapy Combined with Targeted Drugs and Autologous Stem Cell Transplantation (auto-SCT)
Number of Patients:
21
Published:
September 27, 2022
VIEW PUBLICATION
IBCL-117 ASPEN: Long-Term Follow-Up Results of a Phase 3 Randomized Trial of Zanubrutinib vs Ibrutinib in Patients With Waldenström Macroglobulinemia.
Condition:
Waldenström Macroglobulinemia (WM)
Journal:
Clinical lymphoma, myeloma & leukemia
Treatment Used:
Zanubrutinib
Number of Patients:
229
Published:
September 27, 2022
VIEW PUBLICATION
CT-329 CD19-Directed Chimeric Antigen Receptor T Cell Therapy in Waldenström Macroglobulinemia: Initial Experience in Two Clinical Trials.
Condition:
Waldenström Macroglobulinemia (WM)
Journal:
Clinical lymphoma, myeloma & leukemia
Treatment Used:
Chimeric Antigen Receptor (CAR) T Cell Therapy
Number of Patients:
3
Published:
September 27, 2022
VIEW PUBLICATION
Bing-Neel syndrome successfully treated with tirabrutinib.
Condition:
Bing-Neel Syndrome (BNS)
Journal:
[Rinsho ketsueki] The Japanese journal of clinical hematology
Treatment Used:
Tirabrutinib
Number of Patients:
1
Published:
September 04, 2022
VIEW PUBLICATION
Treatment and Survival Outcomes of Waldenstrom Macroglobulinemia in Latin American Patients: A Multinational Retrospective Cohort Study.
Condition:
Waldenstrom Macroglobulinemia (WM) in Latin American Patients
Journal:
JCO global oncology
Treatment Used:
Chemoimmunotherapy
Number of Patients:
159
Published:
August 08, 2022
VIEW PUBLICATION
Complete response with tirabrutinib for relapsed and refractory Bing-Neel syndrome.
Condition:
Bing-Neel Syndrome
Journal:
[Rinsho ketsueki] The Japanese journal of clinical hematology
Treatment Used:
Tirabrutinib
Number of Patients:
1
Published:
August 04, 2022
VIEW PUBLICATION
Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination.
Condition:
Lymphoid Malignancies
Journal:
Journal of hematology & oncology
Treatment Used:
Venetoclax
Number of Patients:
0
Published:
June 06, 2022
VIEW PUBLICATION
First- versus second-generation Bruton tyrosine kinase inhibitors in Waldenström's Macroglobulinemia: A systematic review and meta-analysis.
Condition:
Waldenström's Macroglobulinemia (WM)
Journal:
American journal of hematology
Treatment Used:
First- vs. Second-Generation Bruton Tyrosine Kinase Inhibitors (BTKi)
Number of Patients:
730
Published:
March 31, 2022
VIEW PUBLICATION
SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia.
Condition:
Waldenström Macroglobulinemia (WM)
Journal:
Clinical lymphoma, myeloma & leukemia
Treatment Used:
Targeted Therapies
Number of Patients:
0
Published:
March 27, 2022
VIEW PUBLICATION
Showing 1-12 of 47
Next
Last Updated: 01/20/2023